Autolus Therapeutics plc Stock News

Goldman Sachs Group Inc. boosted its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 5,559.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 650,496 shares of the companys stock after buying an additional 639,002 shares during the quarter. Goldman []

Roblox Corp (NYSE: RBLX) shares jumped 30% after hours on Monday after the company posted robust fiscal Q3 results thanks to demand surge with the easing of COVID-19 restrictions. As a result, the vid

A private equity firm is taking a $100 million stake in the biotech.

Chinese education stocks are moving higher on Monday as reports claim China will allow companies to resume their after-school tutoring. The post Chinese Stocks Alert: The Turnaround Story Driving TAL,

Autolus Therapeutics (AUTL) stock is surging higher in trading Monday following news of a major investment in the company. The post AUTL Stock: Why Little-Known Autolus Therapeutics Is Rocketing Highe

Shares of Autolus Therapeutics plc (NASDAQ: AUTL) jumped about 30% in premarket trading on Monday after it said Blackstone Life Sciences agreed to invest up to $250 million to fund the development of

The stock price of Autolus Therapeutics PLC (NASDAQ: AUTL) increased by over 25% pre-market today. This is why it happened.

- Demonstrates progress on the Company's commercial manufacturing process and builds on positive obe-cel clinical data presented at EHA

Autolus Therapeutics plc (AUTL) CEO Dr. Christian Itin on Q3 2021 Results - Earnings Call Transcript

LONDON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t

- Allowing global commercial launch capacity for obe-cel (AUTO1) - Allowing global commercial launch capacity for obe-cel (AUTO1)

LONDON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced

BASEL, Switzerland--(BUSINESS WIRE)--Novaremed AG, a privately held clinical-stage biopharmaceutical company, announces the acquisition of Metys Pharmaceuticals AG (Metys), including all of its develo

Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q2 2021 Results - Earnings Call Transcript

Potential licensing agreements with Moderna are giving investors reasons to cheer.